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Abstract 
 
Background: To evaluate and compare the efficacy of 
medical and surgical treatment for management of primary 
open angle glaucoma (POAG). 
 
Methods: Study included a total of 32 patients with 60 
eyes, who were divided into two groups. 31 eyes were 
included in group A and were given medical treatment. 29 
eyes were included in group B and were managed with 
primary surgery (Trabeculectomy).  
 
Results: The IOP was controlled in group A with one 
drug in 62.5% (n=10), with two drugs in 25% (n=4)and with 
three drugs in 6.25% (n=1). The IOP of group B patients 
was controlled by surgery alone in 81.25% (n=13) and with 
surgery and drugs in 18.75% (n=3). P values were found to 
be constantly less than 0.001. 
 
Conclusion: Primary surgery i.e. trabeculectomy is a 
superior modality of treatment for POAG as compared to 
medical therapy as it is cost-effective, IOP control is 
uniform and compliance is not a problem.  
 
Keywords: Primary open angle glaucoma. 
Trabeculectomy. Intraocular pressure (IOP). Anti- 
glaucoma medications. 
 
Introduction 
 
Primary open angle glaucoma (POAG) is a 
slowly progressive, usually bilateral disease with an 
insidious onset. It is generally asymptomatic until it 
has caused a significant loss of visual field, although 
some patients may become aware of early defects by  
chance. 1 
POAG is the most common form of glaucoma 
all over the world2,3. It accounts for 60-70% of all 
glaucoma cases. The prevalence in the population 
above the age of 40 Yrs is 0.5 to 1%4. Glaucoma is 
considered to be the fourth largest cause of blindness 
nationwide and is responsible for an estimated 82, 677 
cases.5,6. POAG has a hereditary component.7,8 In 
addition, glaucoma has strong association with 
diabetes mellitus and is also a powerful risk factor for 
cataract, increasing the risk of cataract four folds in a 
population as a whole. 9 
Elevated intraocular pressure is one of the 
major risk factors in causing damage to the optic nerve 
head.10   Persons who are most likely to develop 
POAG than the average person are called POAG 
suspects. They have positive family history, optic disc 
changes, and /or elevated IOP with or without field 
changes.11 When the patient has elevated IOP, optic 
disc cupping and visual field loss, there is no 
controversy that PAOG should be treated. The other 
indications for treatment include the appearance of 
scotomas, progressive cupping without detectable 
visual field loss and a vascular occlusion associated 
with increased IOP. 12,13 
The purpose of treatment of POAG is to 
preserve visual function by controlling IOP and 
thereby preventing or retarding further optic nerve 
damage. Regular and careful follow up is also 
important to ensure that any progression is detected 
early. Topical beta–blockers, parasympathomimetics 
(pilocarpine) are routinely used in our set-up. Newer 
topical agents e.g. dorzolamide (CAI), brimonidine 
(alpha-2 agonist) & latanoprost,bimatoprost and 
travoprost (prostaglandin analogues) along with 
topical combination therapies are expensive and not 
available to most of the patients reporting in Eye 
outpatient department. So use of these medicines is 
confined to selected cases.  Among various surgical 
options, trabeculectomy (with or without 
antimetabolite as an adjunct) is the treatment of choice. 
Argon laser trabeculoplasty is also used if the laser 
facility is available. 
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Patients and Methods 
 
This study was carried out in the Department 
of Ophthalmology,POF Hospital Wah Cantt. from  
April 14  2007 to December 14 2007. Sixty eyes of 
thirty-two patients were recruited in this study. 
For this study the diagnosis of POAG was 
based on intraocular (IOP) exceeding 21 mm of 
Hg, open angle of anterior chamber on 
gonioscopy, visual field defects and progressively 
increasing cupping of the optic disc.The patients 
included belonged to both the sexes. These 
patients included the serving and retired POF 
employees, their families and patients from allied 
departments. 
All patients who had undergone previous 
ocular surgery, trauma or had any other associated 
ocular pathology requiring long-term use of topical 
medications were excluded from the study.The 
patients were divided into two groups, Group A and B. 
It was a double-blind, randomized study with every 
alternate patient selected for primary surgery. These 
patients were evaluated thoroughly by a detailed 
history and thorough clinical examination including 
slit lamp biomicroscopy, gonioscopy and direct 
ophthalmoscopy. IOP was measured with Goldmann 
applanation tonometer. Visual acuity for both near 
and distant vision was also checked. Humphery visual 
field analyzer was used for the evaluation of the visual 
fields and informed written consent was taken in all 
the cases. 
Group A patients (n 16, eyes 31) were given medical 
treatment with Timolol 0.5% topically and the patients 
were evaluated for visual acuity, IOP and evaluation 
of cup-disc ratio on day 1, day 3 and day 7. If after 7 
days of treatment with Timolol 0.5%, IOP remained 
above 21, mm Hg Pilocarpine was also added to the 
drug regimen and thereafter patients were evaluated 
weekly for 4 weeks. If after two weeks of combined 
treatment with 0.5%Timolol and 2% Pilocarpine, the 
IOP still remained above 21 mm Hg, a third agent i.e. 
Prostaglandin Analogue (0.005% Latanoprost ) was 
added to the treatment regimen. These patients were 
followed for another two weeks. If the IOP still 
remained above 21 mm Hg, these patients were 
excluded from the study and were treated surgically. 
Patient compliance with therapy was also checked. 
The patients were asked whether they had used the 
drug on the morning of the visit to the hospital and 
how often they missed their prescribed dose Group B 
patients (n 16, eyes 29) were managed with primary 
surgery (Trabeculectomy). These patients were also 
evaluated on day 1, 3 and 7, and thereafter weekly for 
4 weeks and monthly for 6 months. 
 
Results  
 
The age of the patients ranged from 36 years 
to 78 years, with a peak incidence in the 5th decade of 
life (Table 1). The number of patients decreased after 
the age of 60 years. Out of 32 patients, 24 were males 
and 8 were females, giving a male to female ratio of 3:1 
Patients treated with primary surgery 
(Trabeculectomy) had satisfactory stabilization of IOP, 
showing complete success in 81.25% and qualified 
success in 18.75%, where 0.5% Timolol was required. 
No complication occurred after surgery. As IOP was 
frequently and regularly recorded and an attempt was 
made to keep it within the safe limits, disc or visual 
field deterioration was not seen during the follow-up 
period. The p-values using one tail T test comparing 
two groups i.e. Group A & B was highly significant 
statistically (p<0.001) which shows that these results 
could not have occurred by chance alone. 
 
Table 1: Age Distribution 
Age (yrs) Number of Patients % 
Below 40 3 9.3 
40-50 7 21.8 
51-60 12 37.5 
61-70 6 18.7 
71-80 4 12.5 
In Group A 62.5% patients required only one 
drug for control of IOP (Table 2). 
 
Table  2: Drugs in  Group A 
IOP controlled with Number of patients % 
One Drug 10 62.5 
Two Drugs 4 25 
Three Drugs 1 6.25 
Uncontrolled 1 6.25 
TOTAL 16 100 
6 patients had intraocular pressure more than 
21 mm Hg after 7 days of initiation of therapy with 
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Timolol 0.5%. Therefore Pilocarpine was also added to 
their therapy. The compliance of the patients to the 
medical therapy was not 100%. Only 13 patients had 
complied with the therapy and they never missed a 
single dose.Some patients developed side effects of 
topical medications.1 patient developed eczema of the 
lids, probably due to beta-blockers. Another patient 
had cough and shortness of breath, which got 
aggravated after starting Timolol. Another patient 
developed vertigo. 
Side effects of pilocarpine included headache 
and ocular pain (2 patients each). One patient each 
experienced mild heaviness of head, nausea, running 
nose and sore throat. 
After using Latanoprost, one patient suffered 
from severe irritatation and redness of eyes. Two 
patients were lost in the follow-up one month and 
three months after initiation of treatment. 
In Group B, two patients had ECCE previously 
in one eye and one had retinal detachment surgery in 
one eye previously. Therefore 29 eyes were available 
to undergo primary surgery. After surgery, three 
patients required additional measures to control their 
IOP with Timolol. (Table 3). Two patients were lost to 
follow up No complications were seen after surgery.  
 
Table 3: Management of Group B  
IOP controlled with Number of patients % 
Surgery alone 13 81.25 
Surgery & drugs 3 18.75 
Uncontrolled NIL  
TOTAL 16 100 
 
Discussion 
 
Primary open angle glaucoma is the most 
common form of glaucoma and constitutes 35% of all 
glaucomas 14.Primary open angle glaucoma is one of 
the common causes of blindness 15. Elevated IOP is the 
major risk factor for damage to optic nerve head 
fibbers 16,17 . Therefore the goal of any therapy should 
be to provide the maximum benefit to the largest 
proportion of patients with the least toxicity. 
In our study we compared the results of 
medical therapy vs. surgical treatment for POAG. We 
found a male predominance for POAG (males 75% 
and females 25%). It was probably due to a 
predominantly higher male representation amongst 
patients in POF Hospital. 
The incidence of POAG was found to increase 
with age with a peak in the 5th decade i.e. 37.5%. The 
lesser number of cases after the 7th decade is probably 
due to the decreasing survival in that age. This fact is 
comparable to figures by Hoskins and Kass.18  
In the present study, compliance with 
medication on the day of consulting the doctor was 
75%. It was fractionally better than the overall 
compliance of less than 75%. This is in accordance 
with observations made by Kass et al18. It means that 
IOP reading on the day of examination may be 
misleading and is not truly indicative of patient’s IOP 
status in the few weeks prior to examination. 
Timolol has to be avoided in patients with 
cardiac or pulmonary problems. Timolol is not safe in 
all the cases but the physicians due to its beneficial 
effects on visual fields favour it more . Similarly 
pilocarpine eye drops are intolerable in a small 
percentage of patients, though mild side effects e.g. 
headache, pain in the eyes, nausea occur in significant 
number of cases. Various side effects of systemic 
carbonic anhydrase inhibitors make these agents an 
unpleasant choice for long-term management of 
POAG). In our study, similar side effects were seen in 
group-A patients using one or a combination of 
different agents Out of a total of 16 patients, a single 
drug could manage only 10 patients (62.5%). However 
in these patients few problems were faced. In a few 
cases the frequency of medication had to be increased. 
Some patients suffered side effects and still others had 
poor compliance.  
A significant proportion had more fluctuation 
in IOP before they were satisfactorily controlled with 
two (25%) and three (6.25%) drugs respectively.In this 
study we found complete success in patients treated 
with primary surgery alone (81.25%) and qualified 
success in remaining patients with addition of 0.5% 
Timolol (18.75%). No complication occurred after 
surgery. 
As IOP was frequently and regularly recorded 
and an attempt was made to keep it within the safe 
limits, disc or visual field deterioration was not seen 
during the follow-up period. 
The p-values of individual groups i.e. 
medically controlled and surgically controlled groups 
are highly significant (p<0.001) statistically which 
shows that these results could not have occurred by 
chance alone. These results are consistent with those of 
Lichter et al.19 However, a larger study sample is 
recommended for more reliable results. 
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Conclusions 
 
 Primary surgery i.e. trabeculectomy is a 
superior modality of treatment for POAG as compared 
to medical therapy, where more than one agent is 
frequently needed to stabilize IOP and frequent 
monitoring of IOP is required. In addition, medical 
therapy is associated with problems like non-
compliance and side effects, which leads to difficulty 
in stabilizing the IOP. 
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